Ebola Outbreak “Spreading at Alarming Speed,” WHO Warns — Growing Global Health Emergencies Highlight Rising Need for TOMI’s SteraMist Technology
The World Health Organization (WHO) has issued a warning regarding a rapidly escalating Ebola outbreak in Central Africa, emphasizing the urgent need for advanced environmental disinfection solutions. TOMI Environmental Solutions, Inc. (TOMZ) highlights how this and other global health emergencies, such as Hantavirus, underscore the increasing institutional demand for their SteraMist technology across various sectors. TOMI previously used SteraMist successfully to help contain an Ebola outbreak in West Africa, demonstrating its effectiveness in high-risk environments.
Gamco Investors INC. ET AL Boosts Position in Viasat Inc. $VSAT
Gamco Investors INC. ET AL significantly increased its stake in Viasat Inc. (NASDAQ:VSAT) by 84.3% in the fourth quarter, holding 38,700 shares valued at $1.33 million. Despite a 6.0% dip in trading, Viasat's shares reached a 52-week high, and analysts have a "Moderate Buy" consensus with an average target price of $65.50. Several other institutional investors also increased their holdings in Viasat, while some company insiders sold shares.
Compass Pathways stock hits 52-week high at 11.65 USD By Investing.com
Shares of Compass Pathways Plc (CMPS) reached a 52-week high of $11.65, with a 150% increase in stock price over the past year. Despite this, InvestingPro analysis suggests the stock might be overvalued, and profitability is not anticipated this year. The company reported strong Q1 results, exceeded analyst expectations for EPS, and is progressing with regulatory approvals for its COMP360 treatment for treatment-resistant depression.
Executives from Google, Kaiser Permanente and Urban Outfitters Join GS1 US Board of Governors
The GS1 US Board of Governors has welcomed Senthil Subramanian of Google, Steven Chyung of Kaiser Permanente, and Omar A. Tovar of Urban Outfitters, Inc. as new members. These industry leaders will guide the organization's strategy for digital innovation and supply chain excellence, emphasizing data management, operations, and global logistics. Their diverse experience will be crucial in advancing the adoption and use of GS1 Standards across various sectors like retail, healthcare, and foodservice.
ProShare Advisors LLC Purchases 19,018 Shares of CVS Health Corporation $CVS
ProShare Advisors LLC increased its stake in CVS Health Corporation by 7.7% in the fourth quarter, acquiring an additional 19,018 shares, bringing its total holdings to 264,715 shares valued at $21.0 million. This comes as CVS Health reported strong quarterly results, exceeding revenue and earnings estimates, and raised its FY 2026 EPS guidance. Analysts generally maintain a positive outlook on the company, although insider Tilak Mandadi sold a significant number of shares.
CVS Health Stock Rallies 24% in a Month as Business Turnback Fuels Rebound
CVS Health Corp. (NYSE: CVS) has seen its shares jump 24% in the past month, driven by strong Q1 earnings, a turnaround in its insurance business, and positive analyst upgrades. The company reported better-than-expected revenue and EPS, leading to raised full-year guidance and highlighting improved business fundamentals across all three segments. Despite a notable debt load, analysts believe CVS is poised for further valuation increases due to its integrated healthcare model and attractive dividend yield, making it a compelling long-term investment.
Takeda faces $885m hit after landmark pay-for-delay lawsuit verdict
Takeda has been ordered to pay $885m, potentially rising to $2.5bn, after a US jury found the company liable in a "pay-for-delay" lawsuit related to its constipation drug, Amitiza. The lawsuit, filed by wholesalers and pharmacies, claimed Takeda entered an anticompetitive agreement with generic drugmaker Par Pharma to delay a cheaper version of the drug from reaching the market. Takeda has stated it will appeal the verdict, affirming its belief that the case lacks merit.
Mitsubishi UFJ Asset Management UK Ltd. Sells 12,000 Shares of CVS Health Corporation $CVS
Mitsubishi UFJ Asset Management UK Ltd. significantly reduced its stake in CVS Health Corporation by 75% in Q4, selling 12,000 shares and retaining 4,000 shares valued at $317,000. Despite this sell-off, CVS Health reported strong quarterly results, beating EPS and revenue estimates, and reaffirmed its FY 2026 EPS guidance. Analysts generally maintain a "Moderate Buy" rating for CVS, with several firms raising price targets.
Japan’s Takeda engaged in antitrust scheme to delay generic constipation drug, U.S. jury finds
A U.S. jury found Japan-based Takeda Pharmaceutical liable for approximately $885 million in damages for orchestrating an anticompetitive scheme to delay the release of a generic version of its constipation drug, Amitiza. The lawsuit, part of a wave of "pay-for-delay" cases, concluded that Takeda's settlement with Par Pharmaceutical in 2014 illegally postponed generic competition, causing pharmacies, insurers, health funds, and retailers to overpay for the drug. This verdict marks the first time a jury has found a pharmaceutical company liable in class action litigation over such agreements, with potential damages tripling under U.S. antitrust law.
Inspired Announces CFO Transition
Inspired Entertainment, Inc. announced a CFO transition, with James Richardson stepping down and Craig Wilson promoted to Executive Vice President and Chief Financial Officer, effective May 14, 2026. Wilson, who joined Inspired in 2025, previously held leadership roles at Charles River Laboratories International, Inc. and Walgreens Boots Alliance. He will bring extensive experience in U.S. GAAP, financial reporting, forecasting, and planning to his new role.
CVS Pharmacy retail stores and services explained
CVS Pharmacy combines neighborhood drugstores with in-store health services, vaccinations, and retail options, serving millions of US households. It is the retail pharmacy arm of CVS Health, providing prescription medications, over-the-counter products, and basic wellness checks, while also evolving to integrate more health services into its retail model. The company operates under federal and state regulations, competing with other large chains in the US retail pharmacy market.
XTI Aerospace, Inc. Common Stock - Common Stock (NQ: XTIA)
This page provides recent news headlines related to XTI Aerospace, Inc. (Nasdaq: XTIA), including updates on its stock performance, strategic initiatives, and quarterly results. Key news includes XTI Aerospace's equity stake in an AI-powered autonomous drone maker, recent stock surges, and a significant investment to boost its TriFan aircraft production. The information is sourced from various financial news outlets like Benzinga and InvestorPlace.
Post Holdings CEO Shift Tests Capital Allocation And M&A Playbook
Post Holdings (NYSE: POST) is undergoing a CEO transition from Robert Vitale to Nicolas Catoggio, an internal leader with consulting experience. Investors will be observing how Catoggio manages capital allocation, M&A strategy, and portfolio priorities, especially considering Vitale will remain involved as Executive Chairman. The company has strong recent financial results, including share repurchases and stable guidance, providing Catoggio a solid platform.
Nutriband Inc to Showcase Expanding AI Wellness Product Portfolio and New June Product Launches at ECRM Conference
Nutriband Inc., through its Active Intelligence subsidiary, announced its participation in the June 2026 ECRM conference to showcase its expanding AI wellness product portfolio and new product launches. The company plans to meet with major retailers like Walmart, Walgreens, Amazon, and Cardinal Health to introduce AI Performance Tape, AI Energy Patches, and AI Sleep, aiming to broaden its national retail presence in the rapidly growing wellness market. This move highlights Nutriband's strategy to capitalize on increasing consumer demand for wellness, recovery, and performance solutions.
Tractor Supply shareholders elect board, approve auditor at annual meeting
Tractor Supply Company shareholders recently elected all nominated directors and approved Ernst & Young LLP as their independent auditor for the fiscal year ending December 26, 2026. This comes as the company's shares are trading near their 52-week low. The shareholders also gave a non-binding approval for the compensation of named executive officers, and Meg Ham was appointed to the Audit Committee.
Synergy CHC (Nasdaq: SNYR) files S-1 for 101.7M-share resale and $36M ELOC
Synergy CHC Corp. (Nasdaq: SNYR) has filed an S-1 registration statement for the resale of up to 101.7 million shares of common stock by Hudson Global Ventures, LLC. These shares include 100 million equity line (ELOC) shares, 1.54 million warrant shares, and 170,000 existing shares. While Synergy CHC will not receive proceeds from Hudson's resales, the company can raise up to $36 million over approximately 24 months by selling ELOC shares directly to Hudson. The filing also detailed the company's financial performance, showing a pivot from a net income and positive EBITDA in 2024 to a net loss and negative EBITDA in 2025, attributed partly to bad-debt and inventory write-offs.
Nutriband brings AI wellness tapes and energy patches to Walmart talks
Nutriband (NASDAQ: NTRB) and its Active Intelligence subsidiary will showcase an expanding AI wellness product portfolio, including new AI Performance Tape, AI Energy Patches, and AI Sleep products, at the June 2026 ECRM conference. The company is set to meet with major retailers like Walmart, Walgreens, Amazon, and Cardinal Health to discuss distribution, building on recent international approvals for its AI kinesiology tapes. This move reinforces Nutriband's strategy to commercialize its AI-branded wellness products alongside the development of its AVERSA abuse-deterrent transdermal technology.
Active Intelligence and Nutriband Inc. Showcases Expanding Ai Wellness Product Portfolio and Announces New June Product Launches At Ecrm Conference
Nutriband Inc. and its subsidiary, Active Intelligence, are set to showcase their expanded AI-branded product portfolio and announce new June product launches at the upcoming ECRM conference. The company plans to meet with major retailers and distributors to introduce new products like AI Performance Tape, AI Energy Patches, and AI Sleep, aiming to strengthen its position in the global wellness market. These new offerings are expected to broaden opportunities for national retail placement across multiple high-growth consumer categories.
US jury to decide if Takeda delayed generic constipation drug
A federal jury in Boston is deliberating whether Takeda Pharmaceutical should pay hundreds of millions in damages for an alleged antitrust scheme. Plaintiffs, including pharmacies and insurers, claim Takeda delayed the release of a cheaper generic version of its anti-constipation drug, Amitiza. Takeda argues the settlement was lawful and pro-competition, maintaining that its patents were strong and the deal actually increased competition.
Walmart grows last-mile network with former drug stores
Walmart is expanding its last-mile delivery network by converting former pharmacies and vacant retail spaces into "Walmart Depot" fulfillment hubs. This strategy aims to accelerate grocery and household item deliveries and boost picking efficiency for online orders, strengthening Walmart's competitive edge against Amazon in the fast-delivery market. These depots, typically 20,000 square feet, are not open to the public but serve as rapid fulfillment centers for Spark delivery drivers, stocking essential goods for quick dispatch.
Heartflow in focus as earnings test AI-driven growth strategy
Heartflow Inc. is set to report first-quarter earnings, with investors closely watching its revenue growth, progress on the Plaque Analysis product rollout, and the impact of its patent infringement lawsuit against Cleerly. Analysts expect a wider loss per share but anticipate significant upside from the current stock price, driven by the company's AI-enabled cardiac imaging platform. The earnings call will be crucial in validating Heartflow's commercial acceleration amidst competitive pressures and profitability challenges.
Vanguard Group Inc. Buys 1,358,760 Shares of Xeris Biopharma Holdings, Inc. $XERS
Vanguard Group Inc. increased its stake in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) by 13.8% in the fourth quarter, purchasing an additional 1,358,760 shares and bringing its total holdings to over 11.18 million shares. Several other institutional investors also increased their positions in the company, with 42.75% of the stock now owned by institutions. Xeris Biopharma reported strong quarterly earnings, topping revenue estimates, and currently holds a "Hold" consensus rating from analysts with a price target of $10.80.
CVS Pharmacy: America's Leading Retail Pharmacy Network
CVS Pharmacy, a core part of CVS Health Corp., is highlighted as America's leading retail pharmacy network, offering prescription drugs, over-the-counter products, and clinical services across over 9,000 U.S. locations. The article details its operational model, impact on consumers and the industry through accessibility and cost-efficiency, and its market position amidst global pharmaceutical trends. It services millions annually, plays a crucial role in public health initiatives, and drives efficiencies in pharmacy benefit management.
Becton Dickinson (BIT:1BDX) - Stock Analysis
Becton Dickinson (BIT:1BDX) is trading below its estimated fair value with earnings forecast to grow by 9.63% per year, and pays a reliable dividend of 2.91%. The company recently appointed a new CFO, declared a quarterly dividend, and launched several innovative medical products including the BD CentroVena One Insertion System and the BD PureWick Urine Collection System. Becton Dickinson continues to expand its portfolio with advancements in portal hypertension care, AI-powered immunology research tools, breast biopsy systems, and connected care platforms.
Dermata Therapeutics Provides Corporate Update and Reports Financial Results for the First Quarter 2026
Dermata Therapeutics announced its new direct-to-consumer (DTC) skincare brand, Tome, and plans to launch its first product, the Tome Foundational Treatment, in mid-2026. The company reported financial results for Q1 2026, including raising $2.0 million in net proceeds from ATM financing, which is expected to fund operations into Q1 2027. They also highlighted a decrease in R&D expenses and an increase in SG&A expenses compared to the previous year.
CVS Health Corp stock (US1266501006): Up 3.31% on strong Q1 earnings and raised guidance
CVS Health Corp's stock surged 3.31% following stronger-than-expected Q1 2026 earnings, with revenues of $100.43 billion and adjusted EPS of $2.57, well above analyst forecasts. The company also raised its full-year 2026 guidance, boosting investor confidence. CVS Health operates an integrated healthcare model combining pharmacy benefits, retail pharmacies, and health insurance, positioning it as a defensive play in the healthcare sector.
Surrozen to Present at Upcoming Healthcare Investor Conference
Surrozen, Inc. (Nasdaq: SRZN), a biotechnology company specializing in Wnt signaling therapeutics for ophthalmic conditions, announced that its management will participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference. A fireside chat is scheduled for Tuesday, May 19, 2026, at 11:30 AM Eastern Time, and interested parties can access the live webcast via Surrozen's investor relations website, with a replay available for 30 days.
CVS Health Corp stock (US1266501006): Breaks out with 27% monthly gain and analyst upgrades
CVS Health Corp's stock has surged over 27% in the past month, reclaiming its 50-day moving average and nearing all-time highs around $95, driven by strong technical signals and analyst upgrades. TD Cowen notably raised its price target for CVS to $110. The company's integrated healthcare model, combining pharmacy benefit management, health insurance, and retail pharmacy operations, positions it strongly within the US healthcare market, appealing to investors with its NYSE listing and dividend yield.
Former Rite Aid Location Becoming Dollar Tree In Dover, NH
A former Rite Aid location on Central Avenue in Dover, New Hampshire, is being converted into a Dollar Tree, with signs already visible. Residents have expressed mixed reactions on social media, with some concerns about potential traffic increases. The new store is anticipated to open in July and will require significant remodeling.
McKesson Corporation (NYSE:MCK) Given Average Rating of "Moderate Buy" by Brokerages
McKesson Corporation (NYSE:MCK) has received an average "Moderate Buy" rating from brokerages, with an average 12-month price target of $970.73. Despite beating quarterly EPS estimates and raising fiscal 2027 guidance, the company's stock has faced pressure due to revenue missing expectations and softness in its medical-surgical business. Recent insider sales and plans for a medical-surgical spinoff add to a mixed outlook for investors.
Procter & Gamble Company (The) $PG Shares Sold by C WorldWide Group Holding A S
C WorldWide Group Holding A S significantly reduced its stake in Procter & Gamble, selling 259,845 shares in the fourth quarter. Despite this, analysts maintain a "Moderate Buy" rating for PG with a consensus price target of $161.06, following the company's recent beat on EPS expectations and an increased dividend payout. Insider selling has also been noted, with several executives selling shares totaling approximately $39.7 million in the last 90 days.
PTC Therapeutics (NASDAQ:PTCT) Releases Quarterly Earnings Results, Beats Estimates By $0.42 EPS
PTC Therapeutics (NASDAQ:PTCT) announced strong Q1 earnings, surpassing analyst estimates with an EPS of -$0.03 against a projected -$0.45, and revenue of $272.6 million, exceeding expectations of $218.8 million. The company reported significant year-over-year revenue growth of 43.5% and raised its full-year 2026 guidance, reflecting strong commercial momentum and progress in its pipeline, including accelerating Sephience launch and positive interim data for votoplam. PTC Therapeutics also maintains strong liquidity with $1.89 billion in cash and investments.
Weis Markets reports 42.5% jump in first-quarter profit
Weis Markets reported a significant 42.5% increase in first-quarter net income, reaching $27.85 million, driven by investments in promotional programs and technology. Despite a rise in total revenue to $1.26 billion, the supermarket chain faced challenges from new Medicare pricing rules which reduced pharmacy revenue by approximately $7.48 million. The company's strategy includes continued capital spending on store improvements and infrastructure, with 17 major projects completed in 2025.
Earnings call transcript: ANI Pharmaceuticals beats Q1 2026 expectations
ANI Pharmaceuticals (ANIP) significantly exceeded Q1 2026 expectations, reporting an EPS of $2.05 against a forecast of $1.45, and revenue of $237.5 million, surpassing the $213.42 million projection. The company saw a 4.81% rise in premarket trading and raised its full-year 2026 financial guidance, attributing strong growth to products like Cortrophin Gel and strategic initiatives in rare disease treatments. Executive commentary highlighted the success of their transformation strategy and commitment to growth, while also addressing challenges like increased SG&A expenses and insurance reverification delays.
Jim Cramer’s Big Prediction About CVS Health (CVS) Turned Out To Be Right
Jim Cramer’s prediction about CVS Health (NYSE:CVS) having a strong upcoming quarter proved accurate, as the company surpassed analyst estimates with $100.43 billion in revenue and $2.57 in earnings per share. This success comes amidst a challenging pharmaceutical retail industry, with CVS's stock showing significant gains over the past year and year-to-date. Cramer attributes much of CVS's resilience to its management and its Aetna acquisition.
UBS Group AG Sells 35,156 Shares of Valmont Industries, Inc. $VMI
UBS Group AG reduced its holdings in Valmont Industries, Inc. by 25.3% in the fourth quarter, selling 35,156 shares and retaining 103,656 shares valued at approximately $41.7 million. Valmont Industries exceeded Q4 expectations with an EPS of $5.51 and revenue of $1.03 billion, leading to analyst upgrades and a "Moderate Buy" consensus rating with a target price of $500.33. Additionally, a company director sold a significant number of shares, decreasing insider ownership to 1.42%, yet institutional investors collectively own 87.84% of the company's stock.
Dollar Tree will replace Rite Aid on N. 9th
Dollar Tree is opening a new store at the former Rite Aid location at 415 S. 9th St. in Lebanon, Pennsylvania. This new store will be in addition to its two existing properties in Lebanon City. The company has not yet provided an opening date for the new location.
Earnings call transcript: Horace Mann beats Q1 2026 forecasts with strong growth By Investing.com
Horace Mann (HMN) exceeded Q1 2026 forecasts with an EPS of $1.28 against an expected $1.13, and revenue of $429.3 million, significantly beating the $319.5 million projection. Despite these strong results, including a 20% year-over-year EPS increase and robust growth in Property & Casualty, the stock remained unchanged in after-market trading, suggesting that investors may have already accounted for the positive news or are cautious due to regulatory challenges in California. The company maintained its full-year 2026 EPS guidance and continues to focus on strategic growth initiatives and capital management.
McKesson (NYSE:MCK) Misses Q1 CY2026 Revenue Estimates
McKesson (NYSE: MCK) reported Q1 CY2026 revenue of $96.3 billion, missing analyst estimates of $101.6 billion, despite a 6% year-on-year increase. However, the company's non-GAAP EPS of $11.69 surpassed analyst expectations by 1.1%. The stock remained flat following the mixed results, with adjusted EPS guidance for FY2027 largely in line with analyst predictions.
TScan Therapeutics, Inc. 2026 Q1 10-Q Report: Financials, Risk Factors, and Forward-Looking Statements
TScan Therapeutics, Inc. has released its Q1 2026 financial results, showing a strong cash position of $157.2 million but also an increased accumulated deficit of $533.5 million, typical for a clinical-stage biotechnology company. The report highlights significant risks associated with product development, funding requirements, market volatility, and reliance on third parties. The company's increase in outstanding shares suggests recent fundraising, which could be dilutive but extends its financial runway, making future clinical, regulatory, and financing updates critical for investors.
CVS boosts outlook for 2026 after Aetna profits increase
CVS Health Corp. has raised its earnings outlook for 2026 to $7.30 to $7.50 a share, exceeding analyst expectations, primarily due to better-than-expected profits from its Aetna insurance segment and improved pharmacy business performance. The company's adjusted earnings of $2.57 per share in the first quarter surpassed all estimates. Despite facing regulatory pressure and potential benefit cuts for Medicare Advantage plans, CVS is confident in boosting its margins.
Earnings call transcript: CVS Health Q1 2026 earnings beat expectations
CVS Health reported strong first-quarter 2026 results, exceeding EPS and revenue forecasts, leading to an 8.28% pre-market stock surge and raised full-year guidance. The company's adjusted EPS reached $2.57 on revenues over $100 billion, driven by all operating segments, and management expressed confidence in continued growth and strategic initiatives despite regulatory challenges and medical cost pressures.
Raymond James reiterates Market Perform on PayPal stock after earnings beat
Raymond James has reiterated a Market Perform rating on PayPal (NASDAQ:PYPL) despite the company exceeding first-quarter earnings expectations. While PayPal delivered strong transaction margin and adjusted EPS, the firm expressed concerns about the sustainability of branded checkout and transaction margin dollar growth acceleration, even with the stock trading at a low forward P/E. Other analysts have also offered mixed sentiments, with some reiterating Sell ratings due to operational costs and others maintaining Hold or Market Perform ratings.
Ecovyst Inc. (NYSE:ECVT) Given Average Recommendation of "Moderate Buy" by Brokerages
Ecovyst Inc. (NYSE:ECVT) has received an average "Moderate Buy" recommendation from six brokerages, with an average one-year target price of $14.00. The company recently reported strong quarterly earnings, beating expectations with $0.28 EPS and $199.43 million in revenue, and provided optimistic FY2026 guidance. Institutional ownership of Ecovyst is notably high at 86.69%, with significant recent purchases from several large investment firms.
Amazon Launches Amazon Supply Chain Services, Opening Its Logistics Network to All Businesses
Amazon has launched Amazon Supply Chain Services (ASCS), making its extensive logistics network, previously used for its own operations and third-party sellers, available to all businesses. This initiative allows companies of any size to leverage Amazon's freight, distribution, fulfillment, and parcel shipping solutions to move, store, and deliver products efficiently. Leading brands like Procter & Gamble, 3M, Lands’ End, and American Eagle Outfitters are already utilizing ASCS, aiming to improve speed, reliability, and cost efficiency in their supply chains.
US Bancorp DE Buys 13,440 Shares of CVS Health Corporation $CVS
US Bancorp DE increased its stake in CVS Health Corporation by 7.8% during the fourth quarter, purchasing an additional 13,440 shares to hold a total of 185,868 shares valued at $14.75 million. Other major institutional investors like Vanguard Group Inc. and Capital World Investors also increased their holdings. The report highlights CVS's strong Q4 earnings, positive regulatory tailwinds for Aetna, operational efficiency gains, and a declared quarterly dividend of $0.665.
Hussman Strategic Advisors Inc. Makes New $3.33 Million Investment in CVS Health Corporation $CVS
Hussman Strategic Advisors Inc. initiated a new position in CVS Health Corporation during the fourth quarter, purchasing 42,000 shares valued at approximately $3.33 million. This investment represents 0.8% of Hussman Strategic Advisors' portfolio, making CVS its 13th largest holding. Despite some near-term margin risks and a high payout ratio, analysts broadly maintain a "Moderate Buy" rating for CVS Health, with a consensus target price of $95.05.
PFA Pension Forsikringsaktieselskab Takes $57.58 Million Position in CVS Health Corporation $CVS
PFA Pension Forsikringsaktieselskab recently acquired a new stake of 721,071 shares in CVS Health Corporation, valued at approximately $57.58 million. This investment comes amid varying investor sentiment with positive influences from regulatory tailwinds and operational efficiencies, while concerns exist around near-term margin risks and market valuation. Analysts generally rate CVS Health as a "Moderate Buy" with an average target price of $95.05.
CM Management LLC Decreases Stock Holdings in Iovance Biotherapeutics, Inc. $IOVA
CM Management LLC reduced its stake in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) by 42.9% in the fourth quarter of an unspecified year, selling 300,000 shares. Despite this, other institutional investors increased their positions, with hedge funds and institutions holding 77.03% of the stock. Iovance Biotherapeutics surpassed its latest quarterly EPS and revenue estimates but remains unprofitable, trading near $3.40 with an average analyst "Hold" rating and a consensus target price of $8.88.
Artemis Investment Management LLP Makes New Investment in CVS Health Corporation $CVS
Artemis Investment Management LLP has acquired a new position in CVS Health Corporation, purchasing 74,851 shares valued at approximately $5.94 million in the fourth quarter. This acquisition contributes to institutional investors collectively owning about 80.66% of CVS stock. The article highlights positive aspects such as CVS's Q4 EPS beat, revenue growth, and a $0.665 quarterly dividend, alongside analyst consensus for a "Moderate Buy" rating, while also noting near-term margin pressures and valuation concerns as risks.
